|
1
|
Wöhrer SS, Raderer M and Hejna M:
Palliative chemotherapy for advanced gastric cancer. Ann Oncol.
15:1585–1595. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lum JJ, Bauer DE, Kong M, Harris MH, Li C,
Lindsten T and Thompson CB: Growth factor regulation of autophagy
and cell survival in the absence of apoptosis. Cell. 120:237–248.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Debnath J, Baehrecke EH and Kroemer G:
Does autophagy contribute to cell death? Autophagy. 1:66–74. 2005.
View Article : Google Scholar
|
|
4
|
Levine B and Kroemer G: Autophagy in the
pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
White E and DiPaola RS: The double-edged
sword of autophagy modulation in cancer. Clin Cancer Res.
15:5308–5316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
González-Polo RA, Boya P, Pauleau AL,
Jalil A, Larochette N, Souquère S, Eskelinen EL, Pierron G, Saftig
P and Kroemer G: The apoptosis/autophagy paradox: Autophagic
vacuolization before apoptotic death. J Cell Sci. 118:3091–3102.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maiuri MC, Zalckvar E, Kimchi A and
Kroemer G: Self-eating and self-killing: Crosstalk between
autophagy and apoptosis. Nat Rev Mol Cell Biol. 8:741–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li X and Fan Z: The epidermal growth
factor receptor antibody cetuximab induces autophagy in cancer
cells by downregulating HIF-1alpha and Bcl-2 and activating the
beclin 1/hVps34 complex. Cancer Res. 70:5942–5952. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amaravadi RK, Yu D, Lum JJ, Bui T,
Christophorou MA, Evan GI, Thomas-Tikhonenko A and Thompson CB:
Autophagy inhibition enhances therapy-induced apoptosis in a
Myc-induced model of lymphoma. J Clin Invest. 117:326–336. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jeon HS, Ahn MY, Park JH, Kim TH, Chun P,
Kim WH, Kim J, Moon HR, Jung JH and Kim HS: Anticancer effects of
the MHY218 novel hydroxamic acid-derived histone deacetylase
inhibitor in human ovarian cancer cells. Int J Oncol. 37:419–428.
2010.PubMed/NCBI
|
|
11
|
Park JH, Ahn MY, Kim TH, Yoon S, Kang KW,
Lee J, Moon HR, Jung JH, Chung HY and Kim HS: A new synthetic HDAC
inhibitor, MHY218, induces apoptosis or autophagy-related cell
death in tamoxifen-resistant MCF-7 breast cancer cells. Invest New
Drugs. 30:1887–1898. 2012. View Article : Google Scholar
|
|
12
|
Kim MK, Kang YJ, Kim DH, Hossain MA, Jang
JY, Lee SH, Yoon JH, Chun P, Moon HR, Kim HS, et al: A novel
hydroxamic acid derivative, MHY218, induces apoptosis and cell
cycle arrest through downregulation of NF-κB in HCT116 human colon
cancer cells. Int J Oncol. 44:256–264. 2014.
|
|
13
|
Kumar S: Caspase function in programmed
cell death. Cell Death Differ. 14:32–43. 2007. View Article : Google Scholar
|
|
14
|
Tsujimoto Y: Role of Bcl-2 family proteins
in apoptosis: Apoptosomes or mitochondria? Genes Cells. 3:697–707.
1998. View Article : Google Scholar
|
|
15
|
Thornberry NA and Lazebnik Y: Caspases:
Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Degterev A and Yuan J: Expansion and
evolution of cell death programmes. Nat Rev Mol Cell Biol.
9:378–390. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carew JS, Nawrocki ST and Cleveland JL:
Modulating autophagy for therapeutic benefit. Autophagy. 3:464–467.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH
and Lee JS: Cancer statistics in Korea: Incidence, mortality,
survival, and prevalence in 2011. Cancer Res Treat. 46:109–123.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ropero S and Esteller M: The role of
histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakagawa M, Oda Y, Eguchi T, Aishima S,
Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, et al:
Expression profile of class I histone deacetylases in human cancer
tissues. Oncol Rep. 18:769–774. 2007.PubMed/NCBI
|
|
21
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: Past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU,
Joo HJ and Kim DY: Expression profile of histone deacetylase 1 in
gastric cancer tissues. Jpn J Cancer Res. 92:1300–1304. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song J, Noh JH, Lee JH, Eun JW, Ahn YM,
Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, et al: Increased
expression of histone deacetylase 2 is found in human gastric
cancer. APMIS. 113:264–268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weichert W, Röske A, Gekeler V, Beckers T,
Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of
patterns of class I histone deacetylase expression with patient
prognosis in gastric cancer: A retrospective analysis. Lancet
Oncol. 9:139–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khan O and La Thangue NB: HDAC inhibitors
in cancer biology: Emerging mechanisms and clinical applications.
Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar
|
|
26
|
Slingerland M, Guchelaar HJ and Gelderblom
H: Histone deacetylase inhibitors: An overview of the clinical
studies in solid tumors. Anticancer Drugs. 25:140–149. 2014.
View Article : Google Scholar
|
|
27
|
Grassadonia A, Cioffi P, Simiele F, Iezzi
L, Zilli M and Natoli C: Role of hydroxamate-based histone
deacetylase inhibitors (Hb-HDACIs) in the treatment of solid
malignancies. Cancers (Basel). 5:919–942. 2013. View Article : Google Scholar
|
|
28
|
Nolan L, Johnson PW, Ganesan A, Packham G
and Crabb SJ: Will histone deacetylase inhibitors require
combination with other agents to fulfil their therapeutic
potential? Br J Cancer. 99:689–694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Emanuele S, Lauricella M and Tesoriere G:
Histone deacetylase inhibitors: Apoptotic effects and clinical
implications (Review). Int J Oncol. 33:637–646. 2008.PubMed/NCBI
|
|
30
|
Ellis L and Pili R: Histone deacetylase
inhibitors: Advancing therapeutic strategies in hematological and
solid malignancies. Pharmaceuticals (Basel). 3:2411–2469. 2010.
View Article : Google Scholar
|
|
31
|
Dong G, Wang L, Wang CY, Yang T, Kumar MV
and Dong Z: Induction of apoptosis in renal tubular cells by
histone deacetylase inhibitors, a family of anticancer agents. J
Pharmacol Exp Ther. 325:978–984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu W, Ngo L, Perez G, Dokmanovic M and
Marks PA: Intrinsic apoptotic and thioredoxin pathways in human
prostate cancer cell response to histone deacetylase inhibitor.
Proc Natl Acad Sci USA. 103:15540–15545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shao Y, Gao Z, Marks PA and Jiang X:
Apoptotic and autophagic cell death induced by histone deacetylase
inhibitors. Proc Natl Acad Sci USA. 101:18030–18035. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hrzenjak A, Kremser ML, Strohmeier B,
Moinfar F, Zatloukal K and Denk H: SAHA induces
caspase-independent, autophagic cell death of endometrial stromal
sarcoma cells by influencing the mTOR pathway. J Pathol.
216:495–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang YC, Kong WZ, Xing LH and Yang X:
Effects and mechanism of suberoylanilide hydroxamic acid on the
proliferation and apoptosis of human hepatoma cell line Bel-7402. J
BUON. 19:698–704. 2014.PubMed/NCBI
|
|
36
|
Zhang XD, Gillespie SK, Borrow JM and
Hersey P: The histone deacetylase inhibitor suberic bishydroxamate
regulates the expression of multiple apoptotic mediators and
induces mitochondria-dependent apoptosis of melanoma cells. Mol
Cancer Ther. 3:425–435. 2004.PubMed/NCBI
|
|
37
|
Park H, Lee YJ, Kim TH, Lee J, Yoon S,
Choi WS, Myung CS and Kim HS: Effects of trichostatin A, a histone
deacetylase inhibitor, on the regulation of apoptosis in
H-ras-transformed breast epithelial cells. Int J Mol Med.
22:605–611. 2008.PubMed/NCBI
|
|
38
|
Shen WT, Wong TS, Chung WY, et al:
Valproic acid inhibits growth, induces apoptosis, and modulates
apoptosis-regulatory and differentiation gene expression in human
thyroid cancer cells. Surgery. 138:979–985. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun
SH, Kim HH and Kim IA: Enhanced cytotoxic effect of radiation and
temozolomide in malignant glioma cells: Targeting PI3K-AKT-mTOR
signaling, HSP90 and histone deacetylases. BMC Cancer. 14:172014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
El-Khoury V, Pierson S, Szwarcbart E,
Brons NH, Roland O, Cherrier-De Wilde S, Plawny L, Van Dyck E and
Berchem G: Disruption of autophagy by the histone deacetylase
inhibitor MGCD0103 and its therapeutic implication in B-cell
chronic lymphocytic leukemia. Leukemia. 28:1636–1646. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Watanabe M, Adachi S, Matsubara H, Imai T,
Yui Y, Mizushima Y, Hiraumi Y, Watanabe K, Kamitsuji Y, Toyokuni
SY, et al: Induction of autophagy in malignant rhabdoid tumor cells
by the histone deacetylase inhibitor FK228 through AIF
translocation. Int J Cancer. 124:55–67. 2009. View Article : Google Scholar
|
|
42
|
Degtyarev M, De Mazière A, Orr C, Lin J,
Lee BB, Tien JY, Prior WW, van Dijk S, Wu H, Gray DC, et al: Akt
inhibition promotes autophagy and sensitizes PTEN-null tumors to
lysosomotropic agents. J Cell Biol. 183:101–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mirzoeva OK, Hann B, Hom YK, Debnath J,
Aftab D, Shokat K and Korn WM: Autophagy suppression promotes
apoptotic cell death in response to inhibition of the PI3K-mTOR
pathway in pancreatic adenocarcinoma. J Mol Med Berl. 89:877–889.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fan QW, Cheng C, Hackett C, Feldman M,
Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA,
Debnath J, et al: Akt and autophagy cooperate to promote survival
of drug-resistant glioma. Sci Signal. 3:ra812010.PubMed/NCBI
|
|
45
|
Wu YT, Tan HL, Shui G, Bauvy C, Huang Q,
Wenk MR, Ong CN, Codogno P and Shen HM: Dual role of
3-methylad-enine in modulation of autophagy via different temporal
patterns of inhibition on class I and III phosphoinositide
3-kinase. J Biol Chem. 285:10850–10861. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cheng J, Ohsaki Y, Tauchi-Sato K, Fujita A
and Fujimoto T: Cholesterol depletion induces autophagy. Biochem
Biophys Res Commun. 351:246–252. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mahalingam D, Mita M, Sarantopoulos J,
Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM,
Nawrocki ST, et al: Combined autophagy and HDAC inhibition: A phase
I safety, tolerability, pharmacokinetic, and pharmacodynamic
analysis of hydroxychloroquine in combination with the HDAC
inhibitor vorinostat in patients with advanced solid tumors.
Autophagy. 10:1403–1414. 2014. View Article : Google Scholar : PubMed/NCBI
|
